Clinical efficacy analysis of mesenchymal stem cell therapy in patients with COVID-19: A systematic review

Table 2 Published case reports

Ref.	Age	No. of patients (control)	Regimens (per arm)	Regimens (cell number) dose	Cells infusion	Clinical trial registry	Locations
Zengin et al[28]	72	1	UC-MSCs	0.7 × 106 cells/kg, 0.3 × 106 cells/kg	Intravenous, intratracheal		Acibadem Mehmet Ali Aydinlar University School of Medicine Turkey
Zhang et al[29]	54	1	UC-MSCs (hWJCs)		Intravenous	SH201900594 and SH201900597	Liaocheng People’s Hospital, China
Liang et al[30]	65	1	UC-MSCs	5 × 107/time	Intravenous		Peking University ShenzhenHospital, Shenzhen
Soler Rich et al[31]		1	MSCs (bone marrow)	1 × 106/kg	Intravenous		Spain
Peng et al[32]	66	1	UC-MSCs + CP	1 × 106/kg	Intravenous		Loudi Central Hospital, Hunan
Yilmaz et al[33]	51	1	UC-MSCs (WJ-MSCs)	3 × 106/kg	Intravenous,systemically and intrathecally		Health Science University, Istanbul, Turkey
Zhu et al[34]	48	1	UC-MSCs	1 × 106/kg	Injection	Cell product: 2004L04792, 2006L01037, CXSB1900004	School of Basic Medicine PekingUnion Medical College, Beijing
Tao et al[35]	72	1	UCB-MSCs				Nanjing Medical University, Wuxi, Jiangsu

MSCs: Mesenchymal stem cells; UC-MSCs: Umbilical cord-derived mesenchymal stem cells; hWJCs: Human Wharton's Jelly cells; CP: Convalescent plasma; UCB-MSC: Umbilical cord blood-derived mesenchymal stromal cells; WJ-MSC: Wharton Jelly derived mesenchymal stem cells.